Document is current

Any future updates will be listed below

Zanubrutinib succeeds in head-to-head with ibrutinib in R/R CLL

Crossref DOI link: https://doi.org/10.1038/s41571-022-00724-z

Published Online: 2022-12-21

Published Print: 2023-02

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark